| pubmed-article:9261522 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0005773 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0521447 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C1511698 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0806909 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0205100 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:9261522 | lifeskim:mentions | umls-concept:C1627358 | lld:lifeskim |
| pubmed-article:9261522 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9261522 | pubmed:dateCreated | 1997-9-22 | lld:pubmed |
| pubmed-article:9261522 | pubmed:abstractText | Experimental studies have demonstrated that 5-fluorouracil (5-FU) enhances zidovudine (AZT)-induced DNA strand breaks and cytotoxicity. Phase I studies have demonstrated that the maximum tolerable dose (MTD) of AZT is 8000 mg/sqm when administered i.v. over two hours after weekly 5-FU + l-leucovorin (LV), and that this combination has promising antitumor activity. The purpose of this study was therefore to evaluate the antitumor activity of weekly bolus 5-FU + LV + AZT, administered at its MTD, and to determine whether 5-FU enhances AZT-induced DNA strand breaks in blood nuclear cells. | lld:pubmed |
| pubmed-article:9261522 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9261522 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9261522 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9261522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9261522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9261522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9261522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9261522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9261522 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9261522 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9261522 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:Del TaccaMM | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:MalvaldiGG | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:YonemitsuHH | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:FalconeAA | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:DanesiRR | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:BrunetteMM | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:LencioniMM | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:AllegriniGG | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:PfannerEE | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:AndreuccettiM... | lld:pubmed |
| pubmed-article:9261522 | pubmed:author | pubmed-author:AntonuzzoAA | lld:pubmed |
| pubmed-article:9261522 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9261522 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:9261522 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9261522 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9261522 | pubmed:pagination | 539-45 | lld:pubmed |
| pubmed-article:9261522 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:meshHeading | pubmed-meshheading:9261522-... | lld:pubmed |
| pubmed-article:9261522 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9261522 | pubmed:articleTitle | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. | lld:pubmed |
| pubmed-article:9261522 | pubmed:affiliation | U.O. Oncologia Medica, Ospedale S. Chiara, Pisa, Italy. | lld:pubmed |
| pubmed-article:9261522 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9261522 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9261522 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9261522 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9261522 | lld:pubmed |
